Vir Biotechnology reports positive hepatitis delta trial data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. IVBIY

Go back to Vir Biotechnology reports positive hepatitis delta trial data

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

January 12, 2026 8:00 AM EST

Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants evaluable at 96 Weeks of treatment
New Phase 1 data from PSMA-targeted PRO-XTEN® dual-masked T-cell engager VIR-5500 in prostate cancer to be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in February
Year-end 2025 cash and investments balance of approximately $781M1, with cash runway extended into Q4 2027 as a result of the Norgine licensing agreement and continued disciplined resource deployment

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology,... More